Treatment with the novel TAAR1 agonist ulotaront is associated with reductions in quantitative polysomnographic REM sleep without atonia in healthy human subjects: Results of a post-hoc analysis.

导出 LinkOut

翻译打印收藏纠错

第一作者： John C,Feemster

第一单位： Mayo Center for Sleep Medicine, Departments of Neurology and Medicine, Mayo Clinic College of Medicine, Rochester, MN, USA.

作者： John C,Feemster ^[1] ; Sarah M,Westerland ^[1] ; Thomas R,Gossard ^[1] ; Tyler A,Steele ^[1] ; Paul C,Timm ^[1] ; Jack T,Jagielski ^[1] ; Emma,Strainis ^[1] ; Stuart J,McCarter ^[1] ; Seth C,Hopkins ^[2] ; Kenneth S,Koblan ^[2] ; Erik K,St Louis ^[3]

作者单位： Mayo Center for Sleep Medicine, Departments of Neurology and Medicine, Mayo Clinic College of Medicine, Rochester, MN, USA. ^[1] Sunovion Pharmaceuticals Inc., Marlborough, MA, USA. ^[2] Mayo Center for Sleep Medicine, Departments of Neurology and Medicine, Mayo Clinic College of Medicine, Rochester, MN, USA. Electronic address: StLouis.Erik@mayo.edu. ^[3]

关键词 Polysomnography REM sleep Behavior disorder REM sleep without atonia SEP-363856 Trace amine-associated receptor 1 (TAAR1)Ulotaront

主题词男(雄)性(Male);成年人(Adult);人类(Humans);青年人(Young Adult);睡眠, 快速眼运动(Sleep, REM);肌张力过低(Muscle Hypotonia);REM睡眠行为障碍(REM Sleep Behavior Disorder)

DOI 10.1016/j.sleep.2022.11.022

PMID 36584503

发布时间 2023-02-24

翻译满意度评价：

准确一般字义偏差语意偏离译文作用小提交